Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.10.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) $ (16,608) $ (12,979)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:    
Depreciation 1,266 1,436
Amortization 396 234
Provision for bad debts 1,428 890
Stock-based compensation 731 1,395
Change in fair value of warrant liability and acquisition note payable (2,926) 4,041
Amortization of discount of debt and debt issuance costs 130 185
Loss on sale of assets and India subsidiary 204 0
Modification of 2017 Debt warrants 83 0
Loss in equity method investment 4 21
Loss on extinguishment of debt 0 78
Changes in:    
Accounts receivable 184 (4,029)
Other current assets (237) (606)
Other non-current assets 0 251
Accounts payable, accrued expenses and deferred revenue 3,970 (1,057)
Deferred rent payable and other (64) (109)
Net cash (used in) operating activities (11,439) (10,249)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of fixed assets (799) (1,192)
Patent costs (32) (73)
Purchase of cost method investment 0 (200)
Acquisition of vivoPharm, Pty Ltd., net of cash acquired 0 (656)
Cash received in the sale of India subsidiary, net of cash transferred 1,551 0
Net cash provided by (used in) investing activities 720 (2,121)
CASH FLOWS FROM FINANCING ACTIVITIES    
Principal payments on capital lease obligations (271) (170)
Proceeds from warrant and option exercises 0 1,834
Proceeds from borrowings on Silicon Valley Bank line of credit 6,831 2,000
Repayment of borrowings on Silicon Valley Bank line of credit (8,204) 0
Proceeds from Convertible Note 2,500 0
Advance from NovellusDx, Ltd. 1,500 0
Proceeds from Partners for Growth IV, L.P. term note 0 6,000
Proceeds from Aspire Capital common stock purchases, net of certain offering costs 0 2,965
Principal payments on Silicon Valley Bank term note 0 (4,667)
Payment of debt issuance costs and loan fees 0 (287)
Net cash provided by financing activities 2,356 7,675
Effect of foreign exchange rates on cash and cash equivalents and restricted cash 28 0
Net (decrease) in cash and cash equivalents and restricted cash (8,335) (4,695)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH    
Beginning 9,891 9,502
Ending 1,556 4,807
SUPPLEMENTAL CASH FLOW DISCLOSURE    
Cash paid for interest 827 633
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES    
Fixed assets acquired through capital lease arrangements 150 567
Derivative warrants issued with debt 0 1,004
Acquisition of vivoPharm business 0 9,856
Fair value of warrants reclassified from liabilities to equity 423 0
Beneficial conversion feature on Convertible Note 328 0
Accounts receivable, net 365 0
Other current assets 16 0
Fixed assets, net 608 0
Goodwill 735 0
Other noncurrent assets 98 0
Accounts payable, accrued expenses and deferred revenue (180) 0
Deferred rent and other (13) 0
Loss on sale of India subsidiary (78) 0
Cash received in the sale of India subsidiary, net of cash transferred $ 1,551 $ 0